![](https://investorshub.advfn.com/uicon/423925.png?cb=1539163194)
Friday, May 06, 2022 9:20:27 AM
No actual breakdown is available, but based on available information the US looks like something like this (in 2021, ‘000 USD):
Product revenue, net: 580,320
Cost of goods sold: 121.327
Gross margin: 458.993
Sales and marketing: 258.993
Profit from U.S. commercial activities: 200.000
Inventory (‘000 USD unless stated otherwise):
a.) Certain of the agreements with the suppliers include minimum purchase obligations. These purchases are generally made on the basis of rolling 12-month forecasts which in part are binding on Amarin and the balance of which are subject to adjustment by Amarin subject to certain limitations. Certain of the agreements also include contractual minimum purchase commitments regardless of the rolling 12-month forecasts.
b.) They “introduced” a “new” category in the Balance Sheet by Dec 31, 2021, classify inventory as long-term inventory when consumption of the inventory is expected beyond normal operating cycle..
c.) They spent 288,393 and 75.179 in 2021 and 2022 Q1 respectively. (Please note: Q1 spending was 75% of the net outflow.)
What we could expect in the upcoming quarters?
a.) Commitment: It was 196,100 by Dec 31, 2021 and 49,300 by March 31, 2020 … a 146,800 decrease as result of (i) Q1 spending of 75.179 (ii - more likely) the revised rolling 12-month forecasts (iii - maybe, but not likely) termination of a supply agreement.
I assume that (i) the 49,300 is the contractual minimum purchase commitments regardless of the rolling 12-month forecasts (ii) rolling 12-month forecast is 0 (iii) rolling 12-month forecast equally distributed across quarters (12.325 / Q).
b.) We do not know the duration of the “normal operating cycle” (12 month or 24 months or X months) so the level of the long-term inventory reflects their expectation compared to their previous expectation (not vs. actual trends / data).
c.) I expect 12.325 / Q spending for “goods” during the rest of 2022 (112,154 inc. Q1 vs 288,393 in 2021).
Cash(-flow) [rest of the year, MUSD unless stated otherwise]
They had 389 (consisting of cash and cash equivalents, liquid short-term and long-term investments) as of March 31, 2022.
Based on Q1, available info, etc. my assumption that the operational outflow will be 340 as:
- SG&: 270
- R&D: 30
- “Goods”: 40 (if my assumption is correct and they will not buy top of the minimum commitment *)
Inflow (net revenue) is depending on several factors so I am not making a prediction but a scenario:
A.) 2019 Revenue with 2022 chargebacks: 192. Cash as of Dec 31, 2022: 241
B.) “Flat” revenue: 282. Cash as of Dec 31, 2022: 331
C.) 2021 Revenue less by 20% and with 2022 chargebacks: 332. Cash as of Dec 31, 2022: 381
Best,
G
* the current economic condition supports my assumption since shipping cost are 5-10x higher than 1-2 years ago. It is absolutely realistic and prudent to use the – high level – inventory insteady of higher (new) COGS
Disclosure: I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.
Notice: This post is not investment advice, and not a recommendation to neither buy nor hold nor sell.
Recent AMRN News
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM